TRT claims on TikTok: what the testosterone science actually says

What did @invitewellnessllc actually say?

The creator responded to a viewer whose doctor wanted to start them on TRT and HCG simultaneously. Their core argument: HCG has legitimate clinical uses, but adding it from day one without a specific reason is bad medicine. They said HCG works by mimicking LH to stimulate the Leydig cells, and its main justifications are fertility preservation and maintaining testicular volume. They also mentioned increased semen volume and penile sensitivity as secondary benefits. Their sharpest point was this: "you never want to start off initiating testosterone replacement therapy with a whole bunch of other components" because too many variables make it impossible to know what's actually working. That's a genuinely reasonable clinical position, and they backed it with logic rather than hype.

Does the science back this up?

Mostly, yes. The mechanism is correct, and the primary indications are well-supported. HCG does stimulate Leydig cells, and that pathway is established in endocrinology literature. The fertility and testicular volume claims are solid. The penile sensitivity claim is real but undersupported in controlled trials.

HCG's role in preserving fertility during TRT is well-documented. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, shutting down LH and FSH production. Without LH signaling, intratesticular testosterone drops, and sperm production stalls. HCG restores that signaling. Wenker et al. (2015, Fertility and Sterility) confirmed that HCG co-administration maintained sperm parameters in men on TRT. Testicular volume maintenance follows the same logic and is supported by clinical observation, though large randomized controlled trials are limited.

The penile sensitivity claim is based largely on anecdotal reports and small observational data. It has been attributed to intratesticular testosterone's role in penile tissue health, but it does not have the same evidentiary weight as the fertility and volume claims. The creator does hedge appropriately by saying it "has been noticed" rather than stating it as established fact.

What did they get wrong (or right)?

They got the mechanism right. The LH-mimicking function of HCG and its downstream effect on Leydig cells is textbook endocrinology, confirmed in reviews like Ramasamy et al. (2014, Journal of Urology). They also got the clinical reasoning right. Starting a protocol with multiple active compounds makes troubleshooting nearly impossible, which is a point many TRT prescribers overlook.

One minor error worth flagging: the creator said HCG stimulates the "latic cells," which appears to be a mispronunciation or slip for Leydig cells. That is a cosmetic error, not a factual one, but it could confuse viewers who are new to the terminology.

The penile sensitivity claim is the weakest link here. It is not baseless, but presenting it alongside fertility and testicular volume as a reason to consider HCG implies a similar level of evidence, which does not exist. A more precise communicator would have separated anecdotal observations from clinical indications.

Their closing advice, "be your own advocate, ask why something is being recommended," is genuinely good public health messaging. It applies beyond TRT.

What should you actually know?

If you are starting TRT and you do not have fertility goals or concerns about testicular atrophy, the evidence does not strongly support adding HCG from day one. That does not mean it is wrong in every case, but your provider should have a specific reason for it.

HCG comes with its own side effect profile. It can increase estrogen conversion because Leydig cell stimulation also increases aromatase activity. This can lead to elevated estradiol, which may require additional management. Adding HCG without tracking that can create a cascade of new variables. That is precisely the problem the creator is warning about, and it is a legitimate concern backed by clinical experience.

It is also worth knowing that HCG availability has changed. The FDA reclassified HCG as a biologic in 2020, which affected compounded HCG access in the United States. Some clinics have shifted to using kisspeptin analogs or gonadorelin as alternatives for LH-axis stimulation. These are not equivalent to HCG and have different evidence bases. If your provider is offering one of these as a substitute, ask specifically what the evidence shows for your indication.

Finally, the creator is right that symptom attribution matters. If you start testosterone, HCG, and possibly an aromatase inhibitor at the same time, and you feel better or worse, you have no idea which variable is responsible. Stepwise protocol design is standard in clinical pharmacology for exactly this reason.